Wong Yoke Lan, Pandey Manisha, Choudhury Hira, Lim Wei Meng, Bhattamisra Subrat Kumar, Gorain Bapi
School of Pharmacy, International Medical University, Bukit Jalil, Kuala Lumpur 57000, Malaysia.
Department of Pharmaceutical Technology, School of Pharmacy, International Medical University, Bukit Jalil, Kuala Lumpur 57000, Malaysia.
Polymers (Basel). 2021 Aug 18;13(16):2770. doi: 10.3390/polym13162770.
Hidradenitis suppurativa (HS) has been considered an orphan disease with limited treatments available. The available topical treatment for this condition is clindamycin lotion; however, short retention and frequent application are the main setbacks. Thus, the present study aimed to attain an optimized antibacterial in situ spray formulation for the hidradenitis suppurativa skin condition, which gels once in contact with the skin surface at around 37 °C and possesses bioadhesion as well as sustained-release properties of the incorporated drug. Different concentrations of thermo-reversible gelling polymer, Pluronic F-127, were investigated along with the selected bioadhesive polymers, HPMC and SA. The optimized formulation F3 consisting of 18% Pluronic F-127 with 0.2% HPMC and 0.2% SA was characterized based on various physicochemical properties. The gelation temperature of F3 was found to be 29.0 ± 0.50 °C with a gelation time of 1.35 ± 0.40 min and a pH of 5.8. F3 had the viscosity of 178.50 ± 5.50 cP at 25 °C and 7800 ± 200 cP at 37 °C as the gel set. The optimized formulation was found to be bioadhesive and cytocompatible. Cumulative drug release was 65.05% within the time-frame of 8 h; the release pattern of the drug followed zero-order kinetics with the Higuchi release mechanism. The average zone of inhibition was found to be 43.44 ± 1.34 mm. The properties of F3 formulation reflect to improve residence time at the site of application and can enhance sustained drug release. Therefore, it could be concluded that optimized formulation has better retention and enhanced antimicrobial activity for superior efficacy against HS.
化脓性汗腺炎(HS)一直被认为是一种治疗方法有限的罕见病。针对这种病症现有的局部治疗药物是克林霉素洗剂;然而,药物保留时间短和需频繁涂抹是其主要缺点。因此,本研究旨在为化脓性汗腺炎皮肤病症研发一种优化的原位抗菌喷雾制剂,该制剂在接触约37°C的皮肤表面后会形成凝胶,具有生物黏附性以及所含药物的缓释特性。研究了不同浓度的热可逆凝胶聚合物泊洛沙姆F-127,以及选定的生物黏附聚合物羟丙甲纤维素(HPMC)和海藻酸钠(SA)。基于各种物理化学性质对由18%泊洛沙姆F-127、0.2% HPMC和0.2% SA组成的优化制剂F3进行了表征。发现F3的凝胶化温度为29.0±0.50°C,凝胶化时间为1.35±0.40分钟,pH值为5.8。F3在25°C时的粘度为178.50±5.50厘泊,在37°C凝胶凝固时为7800±200厘泊。发现该优化制剂具有生物黏附性且细胞相容性良好。在8小时的时间范围内累积药物释放率为65.05%;药物释放模式遵循零级动力学和 Higuchi 释放机制。平均抑菌圈为43.44±1.34毫米。F3制剂的特性表明其能延长在应用部位的停留时间并可增强药物缓释。因此,可以得出结论,优化后的制剂具有更好的保留效果和增强的抗菌活性,对治疗HS具有更高的疗效。
Pak J Pharm Sci. 2011-1
Pharmaceuticals (Basel). 2024-1-29
Pharmaceutics. 2025-6-16
Pharmaceutics. 2022-11-16
Polymers (Basel). 2022-11-3
Polymers (Basel). 2022-4-22
Molecules. 2021-6-12
J Oral Biol Craniofac Res. 2021
Polymers (Basel). 2020-10-20
Adv Pharmacol Pharm Sci. 2020-8-6
Turk J Pharm Sci. 2019-9